24
Participants
Start Date
October 31, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
February 28, 2027
MGD020
Administered intravenously at 300mg/kg over 60 minutes.
MGD014
Administered intravenously at 300mg/kg over 60 minutes.
Vorinostat
Administered orally at 400 mg every 72 hours.
Temporary treatment interruption
Discontinuation of antiretroviral therapy (ART) through Week 8. If a participant meets protocol-defined ART restart criteria during the temporary treatment interruption (TTI), ART will be reinitiated immediately. Participants who do not meet restart criteria will remain off ART and continue weekly monitoring until Week 8, at which point ART will be resumed.
RECRUITING
University of North Carolina, Chapel Hill
NOT_YET_RECRUITING
Moi University Clinical Research Center, Eldoret
NOT_YET_RECRUITING
Kenya Medical Research Institute/Walter Reed Project, Kericho
Henry M. Jackson Foundation for the Advancement of Military Medicine
OTHER
US Military HIV Research Program
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
United States Department of Defense
FED
University of North Carolina, Chapel Hill
OTHER